Hansen Camilla Dalby, Lindvig Katrine Prier, Grønbæk Henning, Gluud Lise Lotte, Thiele Maja, Krag Aleksander
Center for Leverforskning, Afdeling for Medicinske Mavetarmsygdomme, Odense Universitetshospital.
Klinisk Institut, Det Sundhedsvidenskabelige Fakultet, Syddansk Universitet.
Ugeskr Laeger. 2022 Oct 17;184(42).
Non-alcoholic fatty liver disease (NAFLD) is the most frequent liver disease in the world, affecting 25% of the population. Around 6% of people with NAFLD will be at risk of developing advanced fibrosis, but symptoms often first occur very late from a decompensated cirrhosis. We need better referral pathways to identify and treat patients with advanced fibrosis. Non-invasive tests such as FIB-4 and NFS can be used in primary care to identify patients who will benefit from a referral to secondary care.
非酒精性脂肪性肝病（NAFLD）是全球最常见的肝脏疾病，影响着25%的人口。约6%的NAFLD患者有发展为晚期肝纤维化的风险，但症状往往在失代偿期肝硬化很晚的时候才首次出现。我们需要更好的转诊途径来识别和治疗晚期肝纤维化患者。FIB-4和NFS等非侵入性检测可用于初级保健，以识别那些将从转诊至二级保健中获益的患者。
